COMPASS Pathways (CMPS) Is Getting Fresh Attention, What Is The Market Weighing?

Simply Wall St.14:20

COMPASS Pathways (NasdaqGS:CMPS) just hit a key milestone, completing its New Drug Application to the U.S. FDA for COMP360 psilocybin in treatment-resistant depression. The news puts regulatory risk ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2682749556?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","is_english":true,"pubTime":"2026-11-12 14:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2682749556","market":"us","top_or_hot":-1,"title":"COMPASS Pathways (CMPS) Is Getting Fresh Attention, What Is The Market Weighing?","media":"Simply Wall St.","content":"<div>\n<p>COMPASS Pathways (NasdaqGS:CMPS) just hit a key milestone, completing its New Drug Application to the U.S. FDA for COMP360 psilocybin in treatment-resistant depression. The news puts regulatory risk ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cmps/compass-pathways/news/compass-pathways-cmps-is-getting-fresh-attention-what-is-the\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COMPASS Pathways (CMPS) Is Getting Fresh Attention, What Is The Market Weighing?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOMPASS Pathways (CMPS) Is Getting Fresh Attention, What Is The Market Weighing?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-12 14:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cmps/compass-pathways/news/compass-pathways-cmps-is-getting-fresh-attention-what-is-the><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>COMPASS Pathways (NasdaqGS:CMPS) just hit a key milestone, completing its New Drug Application to the U.S. FDA for COMP360 psilocybin in treatment-resistant depression. The news puts regulatory risk ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cmps/compass-pathways/news/compass-pathways-cmps-is-getting-fresh-attention-what-is-the\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CMPS","symbol_name":"COMPASS Pathways plc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cmps/compass-pathways/news/compass-pathways-cmps-is-getting-fresh-attention-what-is-the","article_id":"2682749556","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cmps/compass-pathways/news/compass-pathways-cmps-is-getting-fresh-attention-what-is-the","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2682749556","pubTimestamp":1794464446,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"BBailey PembertonNovember 12, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"CMPS":"COMPASS Pathways plc","BK4139":"生物科技","PSIL":"AdvisorShares Psychedelics ETF"},"translate_title":"COMPASS Pathways (CMPS) 受到新的关注，市场权重如何？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PSIL":0.6,"CMPS":1.5},"content_text":"COMPASS Pathways (NasdaqGS:CMPS) just hit a key milestone, completing its New Drug Application to the U.S. FDA for COMP360 psilocybin in treatment-resistant depression. The news puts regulatory risk and timelines in sharper focus for investors. Investors have already been repositioning around COMPASS Pathways, with the 7 day share price return of 19.1% partly reversing a 30 day decline of 16.5% and a 90 day drop of 30.9%. At the same time, the year to date share price gain of 42% and 1 year total shareholder return of 75.8% point to strong but volatile momentum building around the NDA and recent earnings progress. Capitalize on the momentum around COMPASS Pathways by scanning a hand picked 19 high quality undiscovered gems that also focus on breakthrough therapies and strong underlying fundamentals.\nFor COMPASS Pathways, the question is whether this sharp swing reflects improving fundamentals around COMP360 and recent losses, or whether sentiment has simply run ahead of where the valuation now sits. AdvertisementMost Popular Narrative: 62% Undervalued Against a last close of $9.30, the analyst consensus Narrative on Simply Wall St anchors COMPASS Pathways at a fair value of $24.47, implying a wide gap that analysts tie directly to the COMP360 program and its potential earnings power.  COMPASS Pathways currently has no revenue. Analysts are forecasting revenue to reach $284.9 million by July 2029. Analysts are not forecasting that COMPASS Pathways will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate COMPASS Pathways's profit margin will increase from 0.0% to the average US Biotechs industry of 18.9% in 3 years.  See why 15 investors see COMPASS Pathways as 62% undervalued. The fair value in that Narrative is built using a 7.63% discount rate and a long term earnings profile that assumes COMP360 eventually reaches a profit margin close to the wider US Biotechs sector. That framework also bakes in a future P/E of 93.4x on the 2029 earnings estimate of $53.9 million, which is much higher than the 17.6x multiple used for the broader industry in the same analysis. None of these figures are forecasts in themselves, they are the conditions that would need to hold for the $24.47 price target to line up with today’s $9.30 market price. For readers, the key task is to decide whether a very large revenue ramp from $0, combined with that kind of earnings multiple, feels reasonable given COMPASS Pathways’ Phase III and NDA path for COMP360. Result: Fair Value of $24.47 (UNDERVALUED) Still, the narrative around COMPASS Pathways hinges on successful Phase III outcomes and FDA approval, while high cash usage increases the chance of future shareholder dilution. Find out about the key risks to this COMPASS Pathways narrative. Next Steps If the COMPASS Pathways story feels finely balanced between risk and reward, that is exactly the point. This is why you should pressure test the numbers and assumptions yourself, then weigh the 2 key rewards and 4 important warning signs. Looking for more investment ideas beyond COMPASS Pathways? Do not stop your research with COMPASS Pathways. Broaden your watchlist with other potential opportunities that match the kind of risk and reward profile you care about most.  Target potential mispricing by scanning a 32 high quality undervalued stocks that filters for quality fundamentals and attractive P/E levels. Protect your downside by reviewing a 30 resilient stocks with low risk scores that highlights companies with steadier track records and fewer red flags. Strengthen your core holdings by using a list of solid balance sheet and fundamentals (23 results) to focus on businesses with healthier debt and liquidity profiles.  This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2682749556","isCrawlerRequest":true}